Catalent, Inc.
CTLT
Rankning i aktier
#1850
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Aktiekurs
$63.48
Senast synkroniserad: 2024-12-17
Marknadsvärde
$11.52B
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Catalent, Inc. (CTLT)
Kategori
Healthcare
Rörelsemarginal för Catalent, Inc. (CTLT)
Rörelsemarginal per October 2026 TTM: -17.10%
Enligt de senaste finansiella rapporterna och aktiekursen för Catalent, Inc. är företagets nuvarande rörelsemarginal (TTM) -17.10%. Vid slutet av 2023 var rörelsemarginalen -3.20%.
Historik för rörelsemarginal för Catalent, Inc. från 2011 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | -17.10% | 0.00% |
| 2024 | -17.10% | 434.38% |
| 2023 | -3.20% | -144.26% |
| 2022 | 7.23% | -18.31% |
| 2021 | 8.85% | 90.32% |
| 2020 | 4.65% | 89.80% |
| 2019 | 2.45% | -77.75% |
| 2018 | 11.01% | -2.39% |
| 2017 | 11.28% | -4.33% |
| 2016 | 11.79% | -16.97% |
| 2015 | 14.20% | 7.74% |
| 2014 | 13.18% | 16.12% |
| 2013 | 11.35% | -2.83% |
| 2012 | 11.68% | -3.87% |
| 2011 | 12.15% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -101.34% |
IN
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.